The PhysioMimix® benchtop 3D cell culture system from CN Bio has won the Innovation Award at the UK’s largest laboratory event, held at the NEC
CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
London, UK, 19 July 2018: CN Bio Innovations Limited today announced that its Board of Directors has accepted the resignation of Dr Emma Sceats as CEO
CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device
London, UK, 23 May 2018: CN Bio Innovations Limited today launched PhysioMimix, a printer-sized device which allows scientist to conduct organ-on-chip
CN Bio and MIT announce 10 Organ-On-chip platform: Nature Scientific Reports
Organ-on-Chip specialist CN Bio's microfluidic platform for improving drug evaluation has taken a significant step forward. CN Bio's partners at MIT
CN Bio Innovations announces research collaboration with AstraZeneca to validate a new in vitro tool to predict optimised drug dosing regimens for multi-drug therapies
London, UK, November 1 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical
FDA signs collaborative agreement with CN Bio Innovations to use Organs-on-Chips to improve drug development and evaluation
London, UK, October 26 2017: CN Bio Innovations Limited announced today that it has entered into a Research Collaboration Agreement with the US Food
Innovate UK awards grant to CN Bio Innovations and AstraZeneca to use Organs-on-Chips to evaluate the use of existing drugs to treat fatty liver disease
London, UK, October 11 2017: Organ-on-a-Chip specialist CN Bio Innovations Limited announces that Innovate UK has awarded the company a £670,000 grant
CN Bio Innovations announces licence of platform microfluidics technologies from Vanderbilt University
London, UK, October 10 2017: CN Bio Innovations Limited announces that it has licensed from Vanderbilt University three patents and applications, and
CN Bio Innovations announces license of worldwide rights to Hepatitis B programme from Bristol-Myers Squibb
London, UK, April 5 2017: CN Bio Innovations Limited announces that it has licensed from Bristol-Myers Squibb Company a Hepatitis B drug discovery